Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

NPA, NaTrue plan reciprocal natural standards

This article was originally published in The Rose Sheet

Executive Summary

Washington, DC.-based National Products Association and Belgian group NaTrue announce on March 11 their intent to "work toward establishing a mutual recognition agreement" for natural cosmetics. Once the agreement is in effect - targeted for summer of 2010 - products certified to either NPA or NaTrue standards will be recognized by both and permitted to wear both organizations' seals. Relationship will eliminate the need for firms to go through the certification process twice for similar sets of standards and "help consumers at the point of sale in identifying a wider array of truly natural cosmetics," NPA says. NPA has certified more than 340 products and ingredients since May 2008 and NaTrue has certified more than 390 products since September 2008. Both firms say they are in the process of certifying "several hundred" other products

You may also be interested in...



Entries Begin To Roll In For 2024 Industry Awards

Entries have now begun rolling in for the Global Generics & Biosimilars Awards, which returns to Milan this October, Free to enter and attend, the ceremony recognizes the top achievements across the generics, biosimilars and value added medicines industries.

‘I Would Love To Have All The Biologic Assets’ – Formycon’s Glombitza Sets Out Portfolio Approach

In the second part of an exclusive interview, Formycon CEO Stefan Glombitza talks to Generics Bulletin about key regulatory developments in Europe and the US, the firm’s portfolio selection strategy, and upcoming milestones on the horizon.

First Off The Blocks, Fresenius Launches US Tocilizumab Biosimilar

Fresenius Kabi has kicked off competition to Genentech’s Actemra in the US, launching its Tyenne biosimilar version of tocilizumab.

Latest Headlines
See All
UsernamePublicRestriction

Register

RS016793

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel